Relugolix Combination Therapy for Endometriosis-Associated Pelvic Pain
This study is looking at how a medication called Relugolix Combination-Therapy (which contains relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis. You may be able to join if you are a premenopausal woman between 18 and 49 years old with a history of endometriosis and moderate to severe pelvic pain for at least 6 months. The researchers will measure changes in certain inflammation markers (MIP1-α levels) and brain activity (fMRI connectivity) to understand the medication's effects. The study aims to enroll 130 participants, but its current status is unclear.
- Study design
- This is an interventional study. It plans to enroll 130 women.
- What's involved
- Participants will receive study medication for 84 days. Measurements will be taken at the beginning of the study and at week 12.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be assessed at baseline and at a 12-week visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07100782
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Recruiting
PHASE3Ages 18–49InterventionalTreatmentUniversity of MichiganInvestigator-initiated
~130 participants
Updated 2026-02-18 on ClinicalTrials.gov
What's tested:Relugolix CT
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change score in lipopolysaccharide (LPS)-stimulated Macrophage inflammatory protein-1 alpha (MIP1-α) levels
Measured over baseline and week 12 visit
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMichigan1
Study leadership
- Sawsan As-Sanie, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Michigan
- Andrew Schrepf, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Premenopausal woman between age 18 and 49 years (inclusive) at the time of consent. Menopause is defined as amenorrhea \>1 year unrelated to hormonal suppression.
History of endometriosis diagnosed by surgery (visual or biopsy confirmed), ultrasound, or MRI within 10 years of study entry
History of self-reported moderate to severe pelvic pain for ≥ 6 months' duration at time of screening visit.
Willingness to participate in a relugolix CT drug intervention trial
Has not used an injectable hormone therapy in the past 6 months (e.g. DepoProvera®, DepoLupron®).
Willingness to 30-60 day washout interval of oral, vaginal, transdermal, intrauterine hormonal therapies prior to study initiation if applicable
Willingness to use 2 forms of non-hormonal contraception during the entire duration of the study period or has had a history of a bilateral tubal occlusion procedure at least 3 months prior to screening (tubal ligation or hysteroscopic occlusion method)
Willing to undergo quantitative sensory testing (QST), fMRI and other study procedures
Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures
Meet criteria to participate in QST and fMRI. These include:
Normal visual acuity or correctable (with corrective lenses- glasses or contacts) to at least 20/40 for reading instructions in the MRI and visual sensitivity testing
No contraindications to MRI (e.g., metal implants, claustrophobia)
Willingness to refrain from pain medications such as NSAIDs, acetaminophen, and opioids for 12 hours prior to neuroimaging and QST
Willingness to refrain from alcohol and nicotine on day of QST and neuroimaging (alcohol and nicotine consumption is allowed after testing is completed)
Willingness to refrain from physical activity or exercise that would cause muscle and/or joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable)
Able to lie still on their back for 1 hour during MRI
Weigh 300 pounds or less.
\>60% complete entries in daily electronic diary (end-of-day pain, bleeding, fatigue scores)
Minimum of two menstrual flows separated by a minimum of 21 days (d1 bleed to next d1 bleed) during the washout/screening period
Moderate-severe non-menstrual pain and dysmenorrhea confirmed with daily electronic diary in the washout/screening period.
Exclusion
Contraindication to the use of relugolix CT (high risk of arterial or venous thrombotic, or thromboembolic disorder, known osteoporosis, current or history of breast cancer or other hormone sensitive malignancy, known hepatic impairment or disease, undiagnosed abnormal uterine bleeding, known hypersensitivity to components of relugolix CT).
Concurrent participation in other therapeutic trials
Pregnant, lactating, less than 6 months postpartum, or planning a pregnancy within next 12 months
Planning pelvic or abdominal surgery during study period
Prior major surgery in the past 4 months that involves incisions on the abdomen, chest, head, other than a skin biopsy (hysteroscopy, endometrial biopsy is ok to include).
Planning to initiate a new adjunctive pain treatment during study treatment (e.g. cognitive behavioral therapy, physical therapy, acupuncture). Participants may be enrolled if these treatments are completed prior to trial or using stable therapies.
History of hysterectomy and/or bilateral oophorectomy
Clinically significant gynecologic condition such as significant endometrial pathology (e.g. endometrial hyperplasia), persistent ovarian cyst larger than 5 cm, largest uterine dimension \>15 centimeters and not planning an additional intervention or treatment for endometriosis, or another uterine or ovarian condition during the study period. Patients may be enrolled in this study if they were previously successfully treated for these conditions. Patients must have undergone pelvic ultrasound or MRI in the past 6 months, and provide results (or release of records to obtain results)
History or current evidence of psychosis, current suicide risk or attempt within 2 years of study (note: participants with mood disorders such as depression or anxiety will not be excluded)
Chronic opioid, alcohol, and/or illicit drug use
History of substance abuse within past one year
Unable or unwilling to discontinue opioids analgesics within 48 hours of the dense phenotyping study visits
Medical conditions that may significantly interfere with relugolix CT efficacy, ability to fully comply or would make it unsafe for participants to take part in the study, including but not limited to: morbid obesity with Body Mass Index \> 45, uncontrolled autoimmune/inflammatory diseases, significant cardiopulmonary disease (e.g., angina, congestive heart failure, uncontrolled hypertension, severe cardiac valvular disease, Chronic Obstructive Pulmonary Disease (COPD), chronic asthma), renal or liver disease (e.g. cirrhosis, hepatitis), uncontrolled endocrine or allergic disorders (e.g., hypothyroidism, diabetes, allergic rhinitis), neurologic conditions (e.g., multiple sclerosis, prior stroke, neurological tumor), severe physical impairment (e.g., blindness, deafness, paraplegia); and active malignancy (any malignancy except for localized dermatologic cancer).
Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator would prevent safe or satisfactory completion of the study protocol.
Individuals receiving or applying for compensation or disability and other aspects associated with potential secondary gain per self-report;
Additional exclusion that prevent participation in QST and fMRI:
What this trial measures
- Change score in lipopolysaccharide (LPS)-stimulated Macrophage inflammatory protein-1 alpha (MIP1-α) levelsbaseline and week 12 visit
LPS-stimulated MIP1-α levels measured from whole blood
- Change score for functional magnetic resonance imaging (fMRI) connectivity of the somatosensory cortices to the default-mode networkbaseline and week 12 visit
Assessed using a functional connectivity MRI (fcMRI) at rest and applied pain